SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Hims & Hers Health, Inc. operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.

Hims & Hers Health Inc - Ordinary Shares - Class A

Hims & Hers Health Inc

Hims & Hers Health is trending amidst heightened competitive concerns following Amazon Pharmacy's direct offering of Novo Nordisk's GLP-1 weight loss pill, which many in the community view as a significant headwind. While a vocal bearish contingent cites overvaluation and predicts further downside, a segment of investors sees current price levels as a strong buying opportunity, banking on the company's diversified telehealth platform and international expansion. The market is actively debating HIMS's growth trajectory and valuation as it navigates this evolving competitive landscape.

NovaBay Pharmaceuticals, Inc. engages in the development and sales of scientifically-created and clinically-proven eyecare and skincare. Its products include Avenova, NeutroPhase and DERMAdoctor. The company was founded on January 19, 2000 and is headquartered in Emeryville, CA.

Novabay Pharmaceuticals Inc

Novabay Pharmaceuticals (NBY) is experiencing extreme volatility and massive gains, largely fueled by a significant special cash dividend and discussions around a potential pivot to blockchain-based assets. The community is intensely focused on short squeeze potential and the dividend's impact, though many debate the company's underlying fundamentals against the backdrop of its dramatic price movements.

Ondas Holdings, Inc. engages in the development, marketing, and sale of wireless radio systems for secure, wide area mission-critical business-to-business networks. It operates through the Ondas Networks and Ondas Autonomous Systems segments. The Ondas Networks segment provides wireless connectivity solutions enabling mission-critical Industrial Internet applications and services. The Ondas Autonomous Systems segment designs, develops, and markets commercial drone solutions via the Optimus System and Scout System. The company was founded on December 22, 2014 and is headquartered in West Palm Beach, FL.

Ondas Holdings Inc

Ondas Holdings is experiencing significant buzz following a substantial stock and warrant offering to an institutional investor, priced notably above recent trading levels. This move signals strong institutional confidence in the company's future growth, particularly within the burgeoning autonomous drone and defense technology sector. While some debate potential dilution, many in the community are bullish, anticipating major acquisitions and contracts, especially with an investor conference approaching and heightened global defense spending.

TG Therapeutics, Inc. engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1501, TG-1701, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in Morrisville, NC.

TG Therapeutics Inc

TG Therapeutics is trending with investors expressing a mix of frustration over recent stock performance and renewed optimism for Briumvi's competitive standing. The community is actively discussing a competitor's recent regulatory setback, which highlights Briumvi's favorable profile, while anticipating potential strategic updates from the upcoming J.P. Morgan Healthcare Conference.

Oklo, Inc. engages in the development of fission reactors. It provides clean energy through the design and deployment of fast fission power plants. The company was founded by Jacob DeWitte and Caroline Cochran on July 3, 2013 and is headquartered in Santa Clara, CA.

Oklo Inc. - Ordinary Shares - Class A

Oklo Inc.

Oklo Inc. is currently trending due to a significant agreement with Meta Platforms to develop a nuclear energy campus in Ohio, aimed at powering future AI data centers. This deal, alongside anticipated DOE support for fuel and recent discussions on nuclear energy, has fueled intense bullish sentiment regarding the future of small modular reactors for AI infrastructure, despite some community concerns over current revenue and regulatory timelines.

Moonlake Immunotherapeutics operates as a clinical-stage biotechnology company. It offers tri-specific Nanobody, Sonelokimab to address significant unmet needs in inflammatory skin and joint diseases. The company was founded by Kristian Reich, Jorge Santos da Silva, and Arnout Ploos van Amstel in 2021 and is headquartered in Zug, Switzerland.

MoonLake Immunotherapeutics - Ordinary Shares - Class A

MoonLake Immunotherapeutics

MoonLake Immunotherapeutics is seeing a surge in attention following positive FDA feedback, which significantly de-risks its lead asset sonelokimab by clarifying a direct regulatory pathway without additional trials. This catalyst, combined with notable insider buying and multiple analyst upgrades, is driving strong community sentiment and fueling speculation for an imminent buyout or substantial re-rating in the competitive immunology market.

Stafi is the first DeFi protocol unlocking liquidity of staked assets. Users can stake PoS tokens through Stafi and receive rTokens in return, which are available for trading while still earning staking rewards. FIS is the native token on Stafi Chain. FIS is required to provide security to the network by staking, pay for transaction fees on the Stafi chain, mint &amp; redeem rTokens.

StaFi

StaFi (FIS) is currently trending with significant community discussion around its recently announced token burn proposal, aiming for deflationary tokenomics, and a new roadmap. Despite a recent delisting, strong bullish sentiment persists due to its perceived low market cap and continued presence on major exchanges, with many anticipating substantial upside as a liquid staking protocol.

Rich Sparkle Holdings Ltd. engages in the provision of financial printing and corporate services. The firm offers typesetting, proofreading, translation, design, and printing of listing documents, financial reports, fund documents, circulars, and announcements. It also delivers advisory services, such as conducting internal control assessment and environmental, social and governance performance evaluation, and other services including provision of co-working space. The company was founded in 2016 and is headquartered in Hong Kong.

Rich Sparkle Holdings Ltd.

Rich Sparkle Holdings Limited

Rich Sparkle Holdings (ANPA) is trending due to significant momentum following its IPO lock-up expiration, which expanded its publicly traded float, alongside news of a private placement and a strategic acquisition. The community is buzzing with high-stakes discussions, drawing parallels to other volatile Hong Kong-based microcap stocks known for explosive, speculative runs and potential short squeezes.

United States Commodity Funds LLC - United States Oil Fund

United States Oil Fund

The United States Oil Fund is trending as escalating U.S. actions in Venezuela, including military operations and blockades, create market uncertainty. Investors are sharply divided: some anticipate a significant oil price surge due to supply disruptions, while others predict eventual price stabilization or declines if new Venezuelan supply comes online and global oversupply persists. The financial community is closely watching the geopolitical implications of this evolving situation.

Aurinia Pharmaceuticals, Inc. is a clinical stage bio-pharmaceutical company, which engages in the research, development, and commercialization of therapeutic drugs. The company was founded by Robert Foster, Richard Glickman, and Michael Martin on June 16, 1993 and is headquartered in Edmonton, Canada.

Aurinia Pharmaceuticals Inc

Aurinia Pharmaceuticals is trending amid intense buyout speculation, fueled by strong financial performance and anticipation of critical updates on its AUR200 pipeline, particularly regarding planned Phase 2 indications. Community discussion highlights growing frustration with management's perceived lack of transparency, even as the company's strong fundamentals and recent patent lawsuit consolidation position it as a compelling acquisition target in a dynamic biotech M&A environment.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Brandywine Realty Trust (NYSE:BDN) Given Consensus Rating of "Reduce" by Brokerages

Shares of Brandywine Realty Trust (NYSE:BDN - Get Free Report) have been given an average rating of "Reduce" by the five brokerages that are currently covering the company, MarketBeat.com reports...

Brandywine Realty Trust (NYSE:BDN) Upgraded to "Hold" at Wall Street Zen

Wall Street Zen raised shares of Brandywine Realty Trust from a "sell" rating to a "hold" rating in a research report on Saturday...

Brandywine Realty Trust (NYSE:BDN) Hits New 52-Week Low - Time to Sell?

Brandywine Realty Trust (NYSE:BDN) Hits New 1-Year Low - Here's Why...

UiPath Set to Join S&P MidCap 400 and Versant Media Group to Join S&P SmallCap 600

UiPath Set to Join S&P MidCap 400 and Versant Media Group to Join S&P SmallCap 600 UiPath Set to Join S&P MidCap 400 and Versant Media Group to Join S&P SmallCap 600 PR Newswire NEW YORK, Dec. 23...

Brandywine Realty Trust (NYSE:BDN) Sets New 52-Week Low - Here's Why

Brandywine Realty Trust (NYSE:BDN) Hits New 12-Month Low - Here's Why...

Brandywine Realty Trust $BDN Position Lifted by Kawa Capital Management Inc

Kawa Capital Management Inc lifted its stake in Brandywine Realty Trust (NYSE:BDN - Free Report) by 12.1% in the 3rd quarter, according to the company in its most recent filing with the Securities...

Brandywine Realty Trust (NYSE:BDN) Announces $0.08 Quarterly Dividend

Brandywine Realty Trust (NYSE:BDN) declared a quarterly dividend on Wednesday, December 10th. Investors of record on Wednesday, January 7th will be paid a dividend of 0.08 per share by the real...

Brandywine Realty Trust (NYSE:BDN) Sets New 1-Year Low - What's Next?

Brandywine Realty Trust (NYSE:BDN) Sets New 12-Month Low - What's Next...

Brandywine Realty Trust (NYSE:BDN) Sets New 12-Month Low - Time to Sell?

Brandywine Realty Trust (NYSE:BDN) Reaches New 1-Year Low - What's Next...

Brandywine Realty Trust (NYSE:BDN) Receives Consensus Rating of "Reduce" from Analysts

Brandywine Realty Trust (NYSE:BDN - Get Free Report) has earned a consensus rating of "Reduce" from the five research firms that are currently covering the stock, Marketbeat reports. Two analysts...

Brandywine Realty Trust engages in the acquisition, development, redevelopment, ownership, management, and operation of a portfolio of office, life science and lab, residential and mixed-use properties. It operates through the following segments: Philadelphia Central Business District (Philadelphia CBD), Pennsylvania Suburbs, Austin, Texas, and Other. The Philadelphia CBD segment includes properties in Philadelphia, Pennsylvania. The Pennsylvania Suburbs segment refers to the properties in Chester, Delaware, and Montgomery counties. The Austin, Texas segment focuses on properties in the City of Austin, Texas. The Other segment relates to properties located in Washington, D.C., Northern Virginia, Southern Maryland, Camden County, New Jersey and New Castle County, Delaware. The company was founded by Gerard H. Sweeney in 1986 and is headquartered in Philadelphia, PA.

Brandywine Realty Trust

Yes — Rates Move Meaningfully Lower

Short-Term Dip, No Lasting Impact

No — Mostly Political Noise

Other – Comment Below

President Trump says he’s directing $200 billion into mortgage bond purchases to bring down rates and improve housing affordability. With questions around execution, authority, and real market impact, do you think this move will actually lower mortgage rates in 2026?

Will Trump’s Mortgage Bond Plan Actually Lower Rates in 2026?

Current Price	$3.02
Prev Close	$2.92
Open	$2.92
Dividend Yield	10.71%
50-Day Moving Average	$3.20
Beta	1.19
Avg. Volume	4.93M
PE Ratio	-2.72

52-Week High	$5.56
52-Week Low	$2.83
Market Capitalization	$508.71M
EPS (Annual)	-$1.14
Price to Book	0.60
Revenue Per Employee	$1.74M
Enterprise Value/EBITDA	N/A

BDN
Brandywine Realty Trust

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest BDN News

BDNBrandywine Realty Trust